As almost 60% of breast cancer patients are hormone receptor‐positive, antiestrogen drug conjugates hold promise as effective therapeutics.32 Although some tamoxifen drug conjugates display higher potency compared to tamoxifen alone, there remains the risk of tamoxifen drug resistance. This evidence concerns the gene NR4A1 and breast carcinoma.